These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20147614)

  • 1. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
    Bairstow S; McKee J; Nordhaus M; Johnson R
    Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contaminated heparin associated with adverse clinical events and activation of the contact system.
    Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
    N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case study: contamination of heparin with oversulfated chondroitin sulfate.
    Chess EK; Bairstow S; Donovan S; Havel K; Hu P; Johnson RJ; Lee S; McKee J; Miller R; Moore E; Nordhaus M; Ray J; Szabo C; Wielgos T
    Handb Exp Pharmacol; 2012; (207):99-125. PubMed ID: 22566223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
    McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.
    Hogwood J; Naggi A; Torri G; Page C; Rigsby P; Mulloy B; Gray E
    PLoS One; 2018; 13(3):e0193482. PubMed ID: 29494632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anaphylactoid reactions associated with contaminated heparin from China].
    Montpas N; Désormeaux A; Keire D; Adam A
    Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.
    Li B; Suwan J; Martin JG; Zhang F; Zhang Z; Hoppensteadt D; Clark M; Fareed J; Linhardt RJ
    Biochem Pharmacol; 2009 Aug; 78(3):292-300. PubMed ID: 19389385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nanosensor for ultrasensitive detection of oversulfated chondroitin sulfate contaminant in heparin.
    Kalita M; Balivada S; Swarup VP; Mencio C; Raman K; Desai UR; Troyer D; Kuberan B
    J Am Chem Soc; 2014 Jan; 136(2):554-7. PubMed ID: 24127748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
    Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
    Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
    Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
    Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
    Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contaminated heparin.
    Kakkar AK; Bonnefoi M
    N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
    [No Abstract]   [Full Text] [Related]  

  • 20. Outbreak of adverse reactions associated with contaminated heparin.
    Blossom DB; Kallen AJ; Patel PR; Elward A; Robinson L; Gao G; Langer R; Perkins KM; Jaeger JL; Kurkjian KM; Jones M; Schillie SF; Shehab N; Ketterer D; Venkataraman G; Kishimoto TK; Shriver Z; McMahon AW; Austen KF; Kozlowski S; Srinivasan A; Turabelidze G; Gould CV; Arduino MJ; Sasisekharan R
    N Engl J Med; 2008 Dec; 359(25):2674-84. PubMed ID: 19052120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.